

PRESS RELEASE

13 May 2016

Patent Update

Nottingham, UK – 13 May 2016: Oncimmune, a leader in early cancer detection, announces that at an oral hearing before the European Patent Office (EPO) Opposition Division, of one of its 246 patents, European patent EP1731619, has been upheld following a challenge on the grounds of lack of novelty and lack of an inventive step. The Company successfully argued that the broad claims covering Oncimmune's "panel assay" method for detection of cancer-related autoantibodies are both novel and inventive.

Oncimmune has a strong IP position supported by an extensive patent portfolio, consisting of 246 granted patents in eight patent families, as well as unpatented proprietary technology, processes and knowhow. The patents cover 16 territories including the principal territories within Europe, the USA and more recently China.

The challenge to EP1731619 related solely to Europe and it is unchallenged in the USA and other territories. The patent was first filed in 1998 and has an expiry date of 11 May 2019. It initially formed the basis of commercial testing and affords Oncimmune the rights (in the USA and Europe) to measure the presence, or absence, of autoantibodies by contacting a sample of bodily fluid with a panel of any two or more tumour marker antigens in an asymptomatic population (i.e. a screening population).

About Oncimmune

Oncimmune is a leader in early cancer detection. The company has pioneered the development of autoantibody assay technologies that have the potential to allow earlier cancer detection than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, *EarlyCDT[®]-Lung* was launched nationally in the US in 2012. *EarlyCDT[®]-Lung* is available through physicians in the US and also privately in the UK and other regions. *EarlyCDT* tests for liver and ovarian cancer are in final validation.

Oncimmune is headquartered in Nottingham, United Kingdom with testing facilities in the US.

For more information: www.oncimmune.com

Media Contacts:

Chris Gardner, Matthew Neal, Lindsey Neville
Consilium Strategic Communications
oncimmune@consilium-comms.com
+44 (0) 20 3709 5813